Evidence map›Paper›PMID 42510883›Full record

ArticleGenes2026

Toward More Accurate Diagnosis in Neurofibromatosis Type 1: A Dual-Level Analysis of Clinical and Molecular Data with Exploratory Genotype-Phenotype Correlations in a Romanian Cohort.

Lăcrămioara Ionela Butnariu, Ecaterina Grigore, Thomas Gabriel Schreiner, Ludmila Darie, Setalia Popa, Ioana Grigore

Abstract read
In one paragraph

Article in Genes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lăcrămioara Ionela ButnariuGrigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.ORCID 0000-0002-6713-4244
Ecaterina GrigoreGrigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.
Thomas Gabriel SchreinerGrigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.ORCID 0000-0002-4495-4004
Ludmila DarieNeurology, Saint Mary's Emergency Children Hospital, 700309 Iasi, Romania.
Setalia PopaGrigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.ORCID 0000-0002-0743-6777
Ioana GrigoreNeurology, Saint Mary's Emergency Children Hospital, 700309 Iasi, Romania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesNeurofibromatosis type 1 (NF1) is an autosomal dominant disorder caused by pathogenic variants in the

methodsWe present clinical and molecular data from a Romanian cohort of 54 patients initially diagnosed clinically.

resultsPhenotypic evaluation (

conclusionsThe high proportion of sporadic cases (58.3%) in the molecularly tested subgroup underscores the critical role of early genetic screening. By integrating clinical data from 54 patients with the first molecular characterization of NF1 in Romania, this study expands the mutational spectrum and provides preliminary, descriptive insights into genotype-phenotype correlations. It also proposes a cost-effective diagnostic algorithm adapted for resource limited settings and lays the groundwork for future multicenter initiatives. Given the exploratory nature of the molecular subgroup (

Indexed as

Neurofibromatosis 1Neurofibromin 1AdolescentAdultCafe-au-Lait SpotsChildChild, PreschoolCohort StudiesFemaleGenetic Association StudiesGenetic TestingHigh-Throughput Nucleotide SequencingHumansInfantMaleMutationNeurofibromin 1NF1 protein, humangenetic counselinggenotype–phenotype correlationneurofibromatosis type 1next-generation sequencingNF1 genenovel variantRomanian cohort

Identifiers

PMID42510883
PMCPMC13411349

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.